CC-90006 / AnaptysBio, BMS - LARVOL DELTA

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis (clinicaltrials.gov) - P1; N=34; Completed; Sponsor: Celgene; Recruiting ➔ Completed; N=60 ➔ 34

Clinical • Enrollment change • Trial completion

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Celgene; Trial primary completion date: Aug 2019 ➔ Apr 2019

Clinical • Trial primary completion date